Table 1 HHT-related and –unrelated clinical characteristics in the 296 patients with hereditary hemorrhagic telangiectasia (HHT), who responded to the SarsCov-2 infection questionnaire

General (n = 296)

Age years-old, mean (SD); Range

52.94 (17.59); 3–86

Age class, n (%)

 < 40 years

55 (18.6)

 40–64 years

158 (53.4)

 ≥ 65 years

83 (28.0)

Gender (Female), n (%)

157 (53.0)

Clinical, HHT-related (n = 296)^a

Epistaxis, n (%)

283/296 (95.6)

PAVMs, n (%)

100/279 (35.8)

BAVMs, n (%)

27/235 (11.5)

HAVMs, n (%)

104/275 (37.8)

GI bleeding, n (%)

52/296 (17.6)

Mutated Gene (n = 296)

Identified Mutation, n (%)

236 (79.7)

 ENG

86 (36.5)

 ALK1/ACVRL1

149 (63.1)

 SMAD4

1 (0.4)

Mutation unidentified/Ongoing analysis, n (%)

60 (20.3)

Co-morbidity condition, (n = 296)

Absence of Co-morbidity, n (%)

118 (39.9)

Presence of Co-morbidity, n (%)

178 (60.1)

Diabetes, n (%)

82 (27.7)

Hypertension, n (%)

71 (24.0)

Asthma, n (%)

25 (8.4)

History of Stroke, n (%)

8 (2.7)

Smoking, n (%)

43 (14.5)

Obesity, n (%)

33 (11.1)

Renal Insufficiency, n (%)

6 (2.0)

COPD, n (%)

11 (3.7)

Pulmonary Hypertension, n (%)

5 (1.7)

Oncologic Disease, n (%)

10 (3.4)

Other, n (%)

47 (15.9)

< 3 Co-morbidity conditions, n (%)

137 (46.3)

≥ 3 Co-morbidity conditions, n (%)

41 (13.9)